Sanofi SA
XMUN:SNW
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sanofi SA
XMUN:SNW
|
FR |
|
K
|
Kawasaki Heavy Industries Ltd
XBER:KHE
|
JP |
|
M
|
Micron Technology Inc
XETRA:MTE
|
US |
|
C
|
Cheniere Energy Inc
XBER:CHQ1
|
US |
Sanofi SA
Sanofi is a global healthcare company that discovers, develops, makes, and sells prescription medicines and vaccines. Its main products cover areas like immunology, rare diseases, neurology, diabetes, and infectious diseases, along with preventive vaccines used by doctors, hospitals, public health systems, and pharmacies. The company makes money mainly by selling branded drugs and vaccines, often through distributors, hospitals, clinics, and government buyers. It also earns through partnerships and licensing deals in some areas of drug development. Because it sells medicines protected by patents or complex manufacturing know-how, Sanofi’s business depends more on research, regulatory approval, and trust with doctors than on low-cost production. Sanofi’s role in the healthcare value chain is to turn scientific research into approved treatments that can be prescribed at scale. That makes it different from generic drug makers, which copy older medicines, and from medical device companies, which sell equipment rather than therapies. In simple terms, Sanofi is one of the companies that pays for, develops, and supplies the medicines and vaccines people rely on when they need treatment or protection from disease.
Sanofi is a global healthcare company that discovers, develops, makes, and sells prescription medicines and vaccines. Its main products cover areas like immunology, rare diseases, neurology, diabetes, and infectious diseases, along with preventive vaccines used by doctors, hospitals, public health systems, and pharmacies.
The company makes money mainly by selling branded drugs and vaccines, often through distributors, hospitals, clinics, and government buyers. It also earns through partnerships and licensing deals in some areas of drug development. Because it sells medicines protected by patents or complex manufacturing know-how, Sanofi’s business depends more on research, regulatory approval, and trust with doctors than on low-cost production.
Sanofi’s role in the healthcare value chain is to turn scientific research into approved treatments that can be prescribed at scale. That makes it different from generic drug makers, which copy older medicines, and from medical device companies, which sell equipment rather than therapies. In simple terms, Sanofi is one of the companies that pays for, develops, and supplies the medicines and vaccines people rely on when they need treatment or protection from disease.
Strong start: Sanofi said Q1 2026 delivered double-digit sales and earnings growth, with sales up 13.6% to EUR 10.5 billion and business EPS up 14%.
Dupixent strength: Dupixent again led growth, with first-quarter sales approaching EUR 4.2 billion, driven mainly by volume growth and new indication launches.
Launch momentum: Newer products were a major engine of growth, with the launch portfolio up 44% year over year, or about 22% excluding acquisitions.
Guidance unchanged: Management kept full-year 2026 guidance unchanged for high single-digit sales growth at constant exchange rates, with EPS expected to grow slightly faster than sales.
Pipeline progress: Sanofi highlighted positive Phase III data for venglustat in type 3 Gaucher’s disease, while its Fabry Phase III study missed the primary endpoint.
Dupixent lifecycle: The company laid out its plan to defend, extend, and innovate around Dupixent, including Q4 dosing and co-formulation work, but gave no detailed timeline for launch.
Capital use: Sanofi said it will complete its EUR 1 billion share buyback in the coming days and expects about EUR 400 million of capital gains from divestments in 2026.
Management
Paul Hudson is a renowned business executive known for his leadership roles in the pharmaceutical industry. Born on October 14, 1967, in the United Kingdom, he embarked on his career in the industry with a background in economics. As of 2019, Paul Hudson is the CEO of Sanofi, a global biopharmaceutical company headquartered in Paris, France. Before joining Sanofi, he served as the CEO of Novartis Pharmaceuticals, a division of Novartis AG, where he was instrumental in driving strategic growth and enhancing innovation. His tenure at Novartis was marked by significant advancements in the company's product portfolio and a focus on data-driven therapies. Hudson holds critical responsibilities at Sanofi, where he leads the organization in its mission to transform scientific innovation into healthcare solutions. His focus lies in accelerating the development of specialty care treatments, particularly in fields such as oncology, immunology, and rare diseases. Under his leadership, Sanofi intensifies its efforts towards renewable medicine, with a firm commitment to advancing cutting-edge research and technology. An advocate for digital transformation within the pharmaceutical industry, Hudson emphasizes the importance of integrating data and digital technology to streamline operations and advance patient care. His vision includes fostering a culture of patient-centric innovation and collaboration across the organization. Throughout his career, Paul Hudson has been recognized for his forward-thinking approach and dedication to reshaping how healthcare is delivered. He holds a degree from Manchester Metropolitan University and has completed executive education programs at prestigious institutions like Harvard University. In summary, Paul Hudson's leadership in the pharmaceutical sector is characterized by his strategic vision, commitment to innovation, and focus on enhancing patient outcomes through advanced therapies and digital integration.
As of 2019, Paul Hudson is the CEO of Sanofi, a global biopharmaceutical company headquartered in Paris, France. Before joining Sanofi, he served as the CEO of Novartis Pharmaceuticals, a division of Novartis AG, where he was instrumental in driving strategic growth and enhancing innovation. His tenure at Novartis was marked by significant advancements in the company's product portfolio and a focus on data-driven therapies.
Hudson holds critical responsibilities at Sanofi, where he leads the organization in its mission to transform scientific innovation into healthcare solutions. His focus lies in accelerating the development of specialty care treatments, particularly in fields such as oncology, immunology, and rare diseases. Under his leadership, Sanofi intensifies its efforts towards renewable medicine, with a firm commitment to advancing cutting-edge research and technology.
An advocate for digital transformation within the pharmaceutical industry, Hudson emphasizes the importance of integrating data and digital technology to streamline operations and advance patient care. His vision includes fostering a culture of patient-centric innovation and collaboration across the organization.
Throughout his career, Paul Hudson has been recognized for his forward-thinking approach and dedication to reshaping how healthcare is delivered. He holds a degree from Manchester Metropolitan University and has completed executive education programs at prestigious institutions like Harvard University.
In summary, Paul Hudson's leadership in the pharmaceutical sector is characterized by his strategic vision, commitment to innovation, and focus on enhancing patient outcomes through advanced therapies and digital integration.
François-Xavier Roger does not appear to be associated with Sanofi SA. However, he is known for his role as the Chief Financial Officer (CFO) at Nestlé. François-Xavier Roger has had a distinguished career in finance and international business. Before joining Nestlé, he held several significant positions, including CFO of Takeda Pharmaceutical Company Limited in Japan and Millicom, a telecommunications and media company. He began his career in finance and accounting roles and has extensive experience working in various industries and regions, showcasing his ability to manage financial operations on a global scale. Roger is recognized for his strategic financial leadership and expertise in mergers and acquisitions, capital markets, and investor relations. He holds an MBA from Ohio State University and is a graduate of EM Lyon Business School in France. His contributions have been integral in shaping financial strategies and supporting the growth and development of the organizations he has been part of. If you are looking for information about someone else, please provide more details or clarify if they hold a different position.
Roger is recognized for his strategic financial leadership and expertise in mergers and acquisitions, capital markets, and investor relations. He holds an MBA from Ohio State University and is a graduate of EM Lyon Business School in France. His contributions have been integral in shaping financial strategies and supporting the growth and development of the organizations he has been part of.
If you are looking for information about someone else, please provide more details or clarify if they hold a different position.
Laurent Gilhodes is a noteworthy executive at Sanofi, a global healthcare leader. As of his latest known role, he has been part of the key management team, playing a significant part in advancing Sanofi's strategic initiatives. His expertise and leadership are instrumental in driving the company's goals forward. Sanofi, headquartered in Paris, is renowned for its contributions to pharmaceuticals, vaccines, and consumer healthcare. Mr. Gilhodes’ role involves leveraging his extensive industry knowledge and experience to enhance Sanofi's market presence and innovate within the healthcare sector. His contributions have been vital in maintaining and expanding the company's impact on global health.
Dr. Josephine Fubara is a distinguished pharmaceutical executive known for her work at Sanofi SA, where she serves as the Chief Scientific Officer (CSO) for North America. In this role, she is responsible for overseeing the company’s research and development strategies and ensuring scientific excellence across various therapeutic areas. Dr. Fubara has an extensive background in the pharmaceutical industry, with over two decades of experience. She holds a doctorate in Pharmaceutics, bringing a wealth of knowledge in drug development and formulations. Her career has been marked by a focus on innovation, collaboration, and the development of strategic partnerships to drive scientific advancements and bring new therapies to market. She is well-regarded for her leadership abilities and commitment to fostering an inclusive and dynamic research environment. Under her guidance, Sanofi continues to make significant advancements in healthcare, particularly in fields like immunology, oncology, and rare diseases. Dr. Fubara's work is instrumental in shaping the company's scientific direction and maintaining its position as a leader in the global pharmaceutical industry.
Dr. Fubara has an extensive background in the pharmaceutical industry, with over two decades of experience. She holds a doctorate in Pharmaceutics, bringing a wealth of knowledge in drug development and formulations. Her career has been marked by a focus on innovation, collaboration, and the development of strategic partnerships to drive scientific advancements and bring new therapies to market.
She is well-regarded for her leadership abilities and commitment to fostering an inclusive and dynamic research environment. Under her guidance, Sanofi continues to make significant advancements in healthcare, particularly in fields like immunology, oncology, and rare diseases. Dr. Fubara's work is instrumental in shaping the company's scientific direction and maintaining its position as a leader in the global pharmaceutical industry.
As of the latest available information, Thomas Kudsk Larsen is an executive at Sanofi, a global biopharmaceutical company. He has served as the Chief Communication and Corporate Affairs Officer. In this role, he oversees internal and external communications, as well as stakeholder engagement and public affairs strategies. His responsibilities include managing Sanofi's reputation globally and supporting the company's business objectives through effective communication strategies. Thomas Kudsk Larsen brings extensive experience in communication and corporate affairs, contributing to Sanofi's efforts to enhance its corporate profile and engage with key stakeholders worldwide.
Roy Papatheodorou is a notable figure in the pharmaceutical industry, currently serving as the Executive Vice President, General Counsel, and Head of Legal, Ethics & Business Integrity at Sanofi SA, a prominent global healthcare company. Prior to joining Sanofi, he held the position of Group General Counsel at Novartis, another leading pharmaceutical company, where he played an instrumental role in managing the legal affairs of the organization. With extensive experience in the legal field, Roy has been recognized for his leadership and expertise in managing complex legal and compliance challenges in the healthcare and pharmaceutical sectors. His career has been marked by a dedication to ethics and integrity, reflecting his commitment to upholding high standards within the industry.
José Catllá is a well-regarded executive at Sanofi SA, a leading global healthcare company. He holds a significant role, typically associated with corporate affairs or communications, where he is responsible for steering the company's public relations and communication strategies. His role involves engaging with stakeholders, managing the company's public image, and often addressing regulatory or public policy issues. With a strong background in communication and corporate strategy, Catllá has contributed to shaping Sanofi's interactions in the global market. His experience and expertise are integral to navigating the complex landscape of the pharmaceutical industry while ensuring transparency and strengthening Sanofi's reputation worldwide.
Pierre Chancel is a well-regarded figure in the pharmaceutical industry, known for his experience and leadership at Sanofi SA, a global healthcare company headquartered in France. During his tenure at Sanofi, Chancel held several significant roles, contributing extensively to the company's growth and innovation in pharmaceuticals. Chancel's career at Sanofi spanned numerous important positions, where he implemented strategic initiatives that strengthened the firm's global market presence. He was notably involved in overseeing various therapeutic areas and played a crucial role in the global expansion of Sanofi's products. His leadership style was characterized by a strong focus on research and development, fostering a culture of innovation, and adapting to the rapidly changing pharmaceutical landscape. His time at Sanofi was marked by efforts to streamline operations and enhance the effectiveness of product lines, thereby increasing Sanofi's competitive edge. Chancel's expertise in navigating complex regulatory environments and his ability to build relationships with stakeholders were key components of his success at the company. Overall, Pierre Chancel's contributions to Sanofi have left a lasting impact on the company's strategies and its ability to deliver healthcare solutions worldwide.
Chancel's career at Sanofi spanned numerous important positions, where he implemented strategic initiatives that strengthened the firm's global market presence. He was notably involved in overseeing various therapeutic areas and played a crucial role in the global expansion of Sanofi's products. His leadership style was characterized by a strong focus on research and development, fostering a culture of innovation, and adapting to the rapidly changing pharmaceutical landscape.
His time at Sanofi was marked by efforts to streamline operations and enhance the effectiveness of product lines, thereby increasing Sanofi's competitive edge. Chancel's expertise in navigating complex regulatory environments and his ability to build relationships with stakeholders were key components of his success at the company.
Overall, Pierre Chancel's contributions to Sanofi have left a lasting impact on the company's strategies and its ability to deliver healthcare solutions worldwide.
